Abstract Library

#3626 Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu-octreotate peptide radionuclide therapy

Introduction: PRRT has shown favourable results in NETs. Long-term safety and efficacy data for 177Lu-Octreotate PRRT, particularly in combination with chemotherapy, is lacking.

Conference:

Presenting Author: Ransom D

Authors: Ransom D, Kennedy K, Turner J, Macdonald W, Boardman G,

Keywords: PRRT, long term, chemotherapy, leukaemia, myelodysplasia, renal,

#1547 Neuroendocrine Tumours of the Thymus: A Report of Four Cases

Introduction: Neuroendocrine tumours of the thymus (thymic carcinoids) are a rare group of malignancies with a reported incidence of about 1 in 5 million. Over a ten year period in our institution, covering a population of 3.5 million, there had only been two confirmed cases.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Richardson C, Henley G, Jones C, Turner R, Anthoney A,

Keywords: -,

#932 Hematological Toxicity of Combined Lutetium-177 Octreotate Radiopeptide-Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors Followed Long-Term

Introduction: Combination radiopeptide therapy (PRRT) with radiosensitizing chemotherapy of gastroenteropancreatic neuroendocrine tumors (GEP NETs) may improve efficacy, but has the potential to increase myelotoxicity.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Kesavan M

Authors: Kesavan M, Claringbold P, Turner J,

Keywords: PRRT, GEP-NET,

#876 Incidence and Prevalence of Neuroendocrine Tumors (NETs) of the Ileum and Colon (Excluding Appendiceal NETs) in Northern Ireland (NI) Over a 25-Year-Period (1988-2012)

Introduction: Incidence of NETs is quoted to be 2/100,000 with approximately 25% being tumors of the midgut, (0.5/100,000). Incidence is increasing. However, this may be in part due to improved diagnosis but it is also thought to be a true increase.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Ardill J

Authors: Ardill J, Johnston B, Stronge W, Turner G, McCance D,

Keywords: MGC,

#669 Incidence of Second Malignancy in Patients with Neuroendocrine Tumors (NETs) of the Ileum and Colon (MGC)

Introduction: Increased incidence of second malignancy is observed in NETs (Kamp et al 2012).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Ardill J

Authors: Ardill J, Johnston B, Stronge W, Turner G, McCance D,

Keywords: second malignancy, MGC,colon cancer,